VivoSeq
Other

PDAC

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

PDAC is an early-stage landscape with 0 programs across 1 company. The most active players are Revolution Medicines.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Revolution Medicines logo

Revolution Medicines

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Recruiting2 · 40%
Completed1 · 20%
Active, not recruiting1 · 20%
Available1 · 20%

Clinical Trials

Trial Activity

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
Recruiting·UUniversity Hospital, Montpellier·N/A·NCT06287749·37 enrolled
Signature for Precise Chemosensitivity Prediction in PDAC
Completed·RRuijin Hospital·N/A·NCT06461598·365 enrolled
Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.
Active, not recruiting·GERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT04348045·307 enrolled
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
Recruiting·—·Phase 2·NCT07043270·35 enrolled
Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib
Available·Revolution Medicines logoRevolution Medicines·N/A·NCT07573215

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)